These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 30838436)

  • 1. Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.
    Soh HJ; Samuel C; Heaton V; Renton WD; Cox A; Munro J
    Rheumatol Int; 2019 May; 39(5):933-941. PubMed ID: 30838436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disabling pansclerotic morphea of childhood--unusual case and management challenges.
    Forsea AM; Cretu AN; Ionescu R; Giurcaneanu C
    J Med Life; 2008; 1(3):348-54. PubMed ID: 20108512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma.
    Martini G; Saggioro L; Culpo R; Vittadello F; Meneghel A; Zulian F
    Rheumatology (Oxford); 2021 Mar; 60(3):1387-1391. PubMed ID: 32978631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil.
    Martini G; Ramanan AV; Falcini F; Girschick H; Goldsmith DP; Zulian F
    Rheumatology (Oxford); 2009 Nov; 48(11):1410-3. PubMed ID: 19713439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea.
    Arthur M; Fett NM; Latour E; Jacobe H; Kunzler E; Florez-Pollack S; Houser J; Sharma S; Prasad S; Femia A; Stern MJ; Pappas-Taffer LK; Gaffney R; Fernandez AP; Knabel D; Cardones AR; Leung N; Laumann A; Yu JM; Zhao J; Vleugels RA; Tkachenko E; Lo K
    JAMA Dermatol; 2020 May; 156(5):521-528. PubMed ID: 32236497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Pansclerotic Morphea-Clinical Features, Differential Diagnoses and Modern Treatment Concepts.
    Ventéjou S; Schwieger-Briel A; Nicolai R; Christen-Zaech S; Schnider C; Hofer M; Bogiatzi S; Hohl D; De Benedetti F; Morren MA
    Front Immunol; 2021; 12():656407. PubMed ID: 33767715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of Juvenile localized scleroderma and its management.
    Li SC; Zheng RJ
    World J Pediatr; 2020 Feb; 16(1):5-18. PubMed ID: 31786801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paediatric morphoea: a holistic review. Part 2: diagnosis, measures of disease activity, management and natural history.
    Kaushik A; Mahajan R; De D; Handa S
    Clin Exp Dermatol; 2020 Aug; 45(6):679-684. PubMed ID: 32449205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Severe course of a mutilating pansclerotic circumscribed scleroderma in childhood. Clinical aspects and therapy].
    Stücker M; Schreiber D; Gruss C; Freitag M; von Kobyletzki G; Kerscher M; Altmeyer P
    Hautarzt; 1999 Feb; 50(2):131-5. PubMed ID: 10097957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scleroderma in Children and Adolescents: Localized Scleroderma and Systemic Sclerosis.
    Li SC
    Pediatr Clin North Am; 2018 Aug; 65(4):757-781. PubMed ID: 30031497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower lip squamous cell carcinoma in disabling pansclerotic morphea of childhood.
    Petrov I; Gantcheva M; Miteva L; Vassileva S; Pramatarov K
    Pediatr Dermatol; 2009; 26(1):59-61. PubMed ID: 19250408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphea and localized scleroderma in children.
    Vierra E; Cunningham BB
    Semin Cutan Med Surg; 1999 Sep; 18(3):210-25. PubMed ID: 10468041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment in Juvenile Scleroderma.
    Zulian F; Tirelli F
    Curr Rheumatol Rep; 2020 Jun; 22(8):45. PubMed ID: 32591919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma.
    Li SC; Torok KS; Ishaq SS; Buckley M; Edelheit B; Ede KC; Liu C; Rabinovich CE
    Rheumatology (Oxford); 2021 Aug; 60(8):3817-3825. PubMed ID: 33369667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disabling pansclerotic morphea: clinical presentation in two adults.
    Maragh SH; Davis MD; Bruce AJ; Nelson AM
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 1):S115-9. PubMed ID: 16021158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Morphea or juvenile localised scleroderma: Case report].
    Strickler A; Gallo S; Jaramillo P; de Toro G
    Rev Chil Pediatr; 2016; 87(4):279-83. PubMed ID: 26976080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphea in Childhood: An Update.
    Aranegui B; Jiménez-Reyes J
    Actas Dermosifiliogr (Engl Ed); 2018 May; 109(4):312-322. PubMed ID: 29248149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localized and systemic scleroderma.
    Hawk A; English JC
    Semin Cutan Med Surg; 2001 Mar; 20(1):27-37. PubMed ID: 11308134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disabling pansclerotic morphea of children.
    Diaz-Perez JL; Connolly SM; Winkelmann RK
    Arch Dermatol; 1980 Feb; 116(2):169-73. PubMed ID: 7356347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review.
    McGaugh S; Kallis P; De Benedetto A; Thomas RM
    Dermatol Ther; 2022 Jun; 35(6):e15437. PubMed ID: 35278019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.